Semaglutide 7.2mg (Wegovy HD)

Semaglutide 7.2mg (Wegovy HD), FDA approved in April 2026, is Novo Nordisk's strategic answer to Tirzepatide (Zepbound)'s efficacy — delivering 20.7% mean weight loss at 72 weeks, nearly matching the 20.9% of tirzepatide and well above standard Wegovy's 14.9% ceiling. By tripling the dose of the same semaglutide molecule proven in the SELECT trial, it retains the cardiovascular protection profile (20% MACE reduction at 2.4mg) while closing the efficacy gap to within 0.2 percentage points. Administered once-weekly via a modified high-dose pen with gradual titration. Notably, introductory pricing through August 2026 is $149 monthly self-pay — matching Orforglipron (Foundayo)'s oral pill price and making it the highest-efficacy injectable at that price. Post-August 2026 pricing may change. GI side effects align with known semaglutide tolerability. Ideal for patients on standard Wegovy who plateaued and want to step up within the same molecule.